This month’s issue of the Going on Trial newsletter examines personalized therapies for rare conditions, Acadia’s new drug for Rett syndrome and developments in a cord-blood program, among other autism-related drug trial news.
About 1 in 36 children in the United States has autism, up almost 20 percent from the previous estimate, reflecting improved identification, particularly among girls and Black, Hispanic and Asian or Pacific Islander children.
Cannabidiol (CBD) blocks the action of a molecule that drives an overexcitability feedback loop in a rodent model of epilepsy.
Here is a roundup of news and research for the week of 13 March.
Here is a roundup of news and research for the week of 27 February.
This month’s newsletter takes a close look at the orphan drug program in the United States, several cannabis-based therapies and a secondary analysis of bumetanide, among other new developments in autism-related drug trials.
Here is a roundup of news and research for the week of 13 February.
Countries across Latin America and the Caribbean struggle to collect data on autism, but Cecilia Montiel-Nava and the Latin American Autism Spectrum Network are beginning to change that.
The findings put genetic background forward to help explain autism’s heterogeneity.
Serious differences in autism identification persist, according to an analysis of autistic children in New Jersey over 16 years.